Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Creo Medical Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Creo Medical Group şirketinin toplam hissedar öz sermayesi £47.4M ve toplam borcu £14.2M olup, bu da borç-öz sermaye oranını 30% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £69.3M ve £21.9M dir.

Anahtar bilgiler

30.0%

Borç/özkaynak oranı

UK£14.20m

Borç

Faiz karşılama oranı	n/a
Nakit	UK£9.80m
Eşitlik	UK£47.40m
Toplam yükümlülükler	UK£21.90m
Toplam varlıklar	UK£69.30m

Son finansal sağlık güncellemeleri

Is Creo Medical Group (LON:CREO) Weighed On By Its Debt Load?

Oct 06

Creo Medical (LON:CREO) Is In A Good Position To Deliver On Growth Plans

Feb 03

Recent updates

Creo Medical Group PLC (LON:CREO) Screens Well But There Might Be A Catch

Sep 19

Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower

Mar 02

Revenues Tell The Story For Creo Medical Group PLC (LON:CREO) As Its Stock Soars 29%

Dec 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CREO 'nin kısa vadeli varlıkları ( £32.1M ) kısa vadeli yükümlülüklerini ( £9.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: CREO şirketinin kısa vadeli varlıkları ( £32.1M ) uzun vadeli yükümlülüklerini ( £12.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CREO 'nin net borç/öz sermaye oranı ( 9.3% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: CREO şirketinin borç/öz sermaye oranı son 5 yılda 1% seviyesinden 30% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CREO şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: CREO un, serbest nakit akışı her yıl % 13.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Creo Medical Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Creo Medical Group (LON:CREO) Weighed On By Its Debt Load?

Creo Medical (LON:CREO) Is In A Good Position To Deliver On Growth Plans

Recent updates

Consensus EPS estimates fall by 11%

First half 2024 earnings released: UK£0.034 loss per share (vs UK£0.044 loss in 1H 2023)

New minor risk - Shareholder dilution

No longer forecast to breakeven

New minor risk - Share price stability

Micro-Tech (NL) International B.V. entered into a binding agreement to acquire 51% stake in Creo Medical, S.L.U. from Creo Medical Group PLC (AIM:CREO) for €36.7 million.

Creo Medical Group PLC (LON:CREO) Screens Well But There Might Be A Catch

New major risk - Financial position

Creo Medical Group PLC, Annual General Meeting, Jun 26, 2024

Consensus EPS estimates fall by 21%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Creo Medical Group plc Announces Board Changes

Forecast to breakeven in 2026

New minor risk - Financial data availability

Creo Medical Group PLC to Report Fiscal Year 2023 Results on May 15, 2024

New minor risk - Profitability

Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower

Creo Medical Group plc Announces Microwave Lung Ablation Update

New minor risk - Share price stability

Creo Medical Group plc Announces Continued Progress on the Phased Market Release of Its Latest Device, Speedboat® UltraSlim

Forecast to breakeven in 2026

Revenues Tell The Story For Creo Medical Group PLC (LON:CREO) As Its Stock Soars 29%

Creo Medical Group plc Announces First Use of Speedboat UltraSlim in the USA

Creo Medical Group PLC Announces the Initiation of Its Commercial Launch of Speedboat Ultraslim

Creo Medical Group plc Receives 510(K) Clearance from the Us Food & Drug Administration for Its Speedboat Ultraslim Device

Creo Medical Group plc Announces EU Launch Accelerated by 18 Months Eu Regulatory Pathway for Launch Early 2024

Is Creo Medical Group (LON:CREO) Weighed On By Its Debt Load?

First half 2023 earnings released: UK£0.044 loss per share (vs UK£0.074 loss in 1H 2022)

Creo Medical Group PLC to Report First Half, 2023 Results on Sep 12, 2023

Creo Medical Group PLC, Annual General Meeting, Jun 27, 2023

Creo Medical Group plc Announces First In-Human Milestone Reaches for Microblate Flex as Part of Lung Tissue Ablation Clinical Study

Full year 2022 earnings: EPS misses analyst expectations

Key Executive recently bought UK£543k worth of stock

Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023

Creo Medical Group PLC has completed a Follow-on Equity Offering in the amount of £28.5 million.

Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023

Less than half of directors are independent

Creo Medical Limited, Annual General Meeting, Jun 28, 2022

Creo Medical Limited to Report Fiscal Year 2021 Results on May 23, 2022

Less than half of directors are independent

Creo Medical Limited has completed a Follow-on Equity Offering in the amount of £5.06601 million.

Creo Medical Limited has completed a Follow-on Equity Offering in the amount of £31.250001 million.

New 90-day high: UK£2.23

Creo Medical (LON:CREO) Is In A Good Position To Deliver On Growth Plans

New 90-day high: UK£2.12

Creo Medical Group plc Receives US FDA clearance for MicroBlate™ Flex device

How Many Creo Medical Limited (LON:CREO) Shares Do Institutions Own?

New 90-day high: UK£2.08

New 90-day low: UK£1.67

First half earnings released

New 90-day low: UK£1.72

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin